JNJ
Johnson & Johnson
NYSE: JNJ · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$271.04
+0.86% today
Updated 2026-10-28
Market cap
$615.87B
P/E ratio
38.78
P/S ratio
6.20x
EPS (TTM)
$6.59
Dividend yield
0.51%
52W range
$181 – $281
Volume
7.0M
Johnson & Johnson (JNJ) Insider transactions
Net insider activity
Net selling (406,704 shares)
Buy transactions
47
Sell transactions
53
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-08 | WOODS, EUGENE A. | Director | Buy | 136 | $276.31 | $37578.16 |
| 2026-09-08 | PINTO, DANIEL E | Director | Buy | 113 | $276.31 | $31223.03 |
| 2026-09-08 | HEWSON, MARILLYN A | Director | Buy | 181 | $276.31 | $50012.11 |
| 2026-09-02 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Sale | 22,527 | — | — |
| 2026-09-02 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Sale | 11,070 | — | — |
| 2026-09-02 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Sale | 22,527 | $274.74 | $6.19M |
| 2026-09-02 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Buy | 11,070 | $131.94 | $1.46M |
| 2026-08-17 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Sale | 15,000 | — | — |
| 2026-08-17 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Sale | 15,000 | $263.36 | $3.95M |
| 2026-08-13 | DUATO, JOAQUIN | Director, CEO and Chairman of the Board | Sale | 123,291 | — | — |
| 2026-08-13 | DUATO, JOAQUIN | Director, CEO and Chairman of the Board | Buy | 123,291 | $115.67 | $14.26M |
| 2026-08-13 | DUATO, JOAQUIN | Director, CEO and Chairman of the Board | Sale | 102,315 | $261.00 | $26.70M |
| 2026-08-13 | DUATO, JOAQUIN | Director, CEO and Chairman of the Board | Sale | 20,976 | $262.00 | $5.50M |
| 2026-08-06 | FORMINARD, ELIZABETH | EVP, Chief Legal Officer | Sale | 9,344 | — | — |
| 2026-08-06 | FORMINARD, ELIZABETH | EVP, Chief Legal Officer | Sale | 9,344 | $257.76 | $2.41M |
| 2026-08-06 | FORMINARD, ELIZABETH | EVP, Chief Legal Officer | Sale | 6,574 | $255.93 | $1.68M |
| 2026-08-05 | DUATO, JOAQUIN | Director, CEO and Chairman of the Board | Sale | 41,957 | $258.06 | $10.83M |
| 2026-08-05 | DUATO, JOAQUIN | Director, CEO and Chairman of the Board | Sale | 6,523 | $258.74 | $1.69M |
| 2026-07-20 | BROADHURST, VANESSA | EVP, Global Corp Affairs | Sale | 11,925 | — | — |
| 2026-07-20 | BROADHURST, VANESSA | EVP, Global Corp Affairs | Sale | 11,129 | — | — |
| 2026-07-20 | BROADHURST, VANESSA | EVP, Global Corp Affairs | Sale | 23,054 | $251.27 | $5.79M |
| 2026-07-20 | BROADHURST, VANESSA | EVP, Global Corp Affairs | Buy | 11,925 | $131.94 | $1.57M |
| 2026-07-20 | BROADHURST, VANESSA | EVP, Global Corp Affairs | Buy | 11,129 | $129.51 | $1.44M |
| 2026-06-11 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Sale | 10,000 | — | — |
| 2026-06-11 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Buy | 10,000 | $115.67 | $1.16M |
| 2026-06-09 | WOODS, EUGENE A. | Director | Buy | 161 | $232.79 | $37479.19 |
| 2026-06-09 | PINTO, DANIEL E | Director | Buy | 134 | $232.79 | $31193.86 |
| 2026-06-09 | HEWSON, MARILLYN A | Director | Buy | 215 | $232.79 | $50049.85 |
| 2026-05-01 | REED, JOHN C | EVP, Innovative Medicine, R&D | Sale | 25,255 | — | — |
| 2026-05-01 | REED, JOHN C | EVP, Innovative Medicine, R&D | Buy | 25,255 | — | — |
| 2026-05-01 | REED, JOHN C | EVP, Innovative Medicine, R&D | Sale | 11,002 | $229.85 | $2.53M |
| 2026-04-23 | WOODS, EUGENE A. | Director | Buy | 975 | — | — |
| 2026-04-23 | WEST, NADJA | Director | Buy | 975 | — | — |
| 2026-04-23 | WEINBERGER, MARK A | Director | Buy | 975 | — | — |
| 2026-04-23 | PINTO, DANIEL E | Director | Buy | 1,712 | — | — |
| 2026-04-23 | MORIKIS, JOHN G | Director | Buy | 1,540 | — | — |
| 2026-04-23 | MCCLELLAN, MARK B. | Director | Buy | 975 | — | — |
| 2026-04-23 | JOLY, HUBERT | Director | Buy | 975 | — | — |
| 2026-04-23 | JOHNSON, PAULA A | Director | Buy | 975 | — | — |
| 2026-04-23 | HEWSON, MARILLYN A | Director | Buy | 975 | — | — |
| 2026-04-23 | DOUDNA, JENNIFER A | Director | Buy | 975 | — | — |
| 2026-04-23 | BECKERLE, MARY C | Director | Buy | 975 | — | — |
| 2026-03-10 | WOODS, EUGENE A. | Director | Buy | 155 | $242.14 | $37531.70 |
| 2026-03-10 | PINTO, DANIEL E | Director | Buy | 129 | $242.14 | $31236.06 |
| 2026-03-10 | HEWSON, MARILLYN A | Director | Buy | 206 | $242.14 | $49880.84 |
| 2026-02-27 | DECKER, ROBERT J | VP Corporate Controller | Sale | 4,075 | — | — |
| 2026-02-27 | DECKER, ROBERT J | VP Corporate Controller | Buy | 4,075 | $115.67 | $471355.25 |
| 2026-02-20 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Sale | 1,322 | $245.66 | $324762.52 |
| 2026-02-18 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Sale | 13,625 | — | — |
| 2026-02-18 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Sale | 8,998 | — | — |
| 2026-02-18 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Buy | 13,625 | $115.67 | $1.58M |
| 2026-02-18 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Buy | 8,998 | $129.51 | $1.17M |
| 2026-02-17 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 33,386 | — | — |
| 2026-02-17 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 19,241 | — | — |
| 2026-02-17 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 12,066 | — | — |
| 2026-02-17 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 33,386 | $242.75 | $8.10M |
| 2026-02-17 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 24,961 | $242.68 | $6.06M |
| 2026-02-17 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 19,241 | $242.99 | $4.68M |
| 2026-02-17 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 12,066 | $242.87 | $2.93M |
| 2026-02-17 | SWANSON, JAMES D. | EVP, CIO | Sale | 20,521 | — | — |
| 2026-02-17 | SWANSON, JAMES D. | EVP, CIO | Buy | 20,521 | $164.62 | $3.38M |
| 2026-02-17 | REED, JOHN C | EVP, Innovative Medicine, R&D | Sale | 29,927 | — | — |
| 2026-02-17 | REED, JOHN C | EVP, Innovative Medicine, R&D | Sale | 21,721 | — | — |
| 2026-02-17 | REED, JOHN C | EVP, Innovative Medicine, R&D | Sale | 29,927 | $243.00 | $7.27M |
| 2026-02-17 | REED, JOHN C | EVP, Innovative Medicine, R&D | Sale | 21,721 | $243.00 | $5.28M |
| 2026-02-17 | REED, JOHN C | EVP, Innovative Medicine, R&D | Sale | 2,283 | $243.00 | $554769.00 |
| 2026-02-17 | BROADHURST, VANESSA | EVP, Global Corp Affairs | Sale | 6,197 | $243.39 | $1.51M |
| 2026-02-15 | WOLK, JOSEPH J | Exec VP, CFO | Buy | 3,863 | — | — |
| 2026-02-15 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 1,971 | — | — |
| 2026-02-15 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 1,878 | — | — |
| 2026-02-15 | WOLK, JOSEPH J | Exec VP, CFO | Buy | 53,793 | — | — |
| 2026-02-15 | WOLK, JOSEPH J | Exec VP, CFO | Buy | 1,971 | — | — |
| 2026-02-15 | WOLK, JOSEPH J | Exec VP, CFO | Buy | 1,878 | — | — |
| 2026-02-15 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 858 | $243.45 | $208880.10 |
| 2026-02-15 | WOLK, JOSEPH J | Exec VP, CFO | Sale | 817 | $243.45 | $198898.65 |
| 2026-02-15 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Buy | 1,217 | — | — |
| 2026-02-15 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Sale | 635 | — | — |
| 2026-02-15 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Sale | 606 | — | — |
| 2026-02-15 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Buy | 16,945 | — | — |
| 2026-02-15 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Buy | 635 | — | — |
| 2026-02-15 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Buy | 606 | — | — |
| 2026-02-15 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Sale | 325 | $243.45 | $79121.25 |
| 2026-02-15 | WENGEL, KATHRYN E | EVP, Chief TO and Risk Officer | Sale | 310 | $243.45 | $75469.50 |
| 2026-02-15 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Buy | 3,940 | — | — |
| 2026-02-15 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Sale | 1,847 | — | — |
| 2026-02-15 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Sale | 1,594 | — | — |
| 2026-02-15 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Buy | 54,869 | — | — |
| 2026-02-15 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Buy | 1,847 | — | — |
| 2026-02-15 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Buy | 1,594 | — | — |
| 2026-02-15 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Sale | 945 | $243.45 | $230060.25 |
| 2026-02-15 | TAUBERT, JENNIFER L | EVP, WWC. Innovative Medicine | Sale | 816 | $243.45 | $198655.20 |
| 2026-02-15 | SWANSON, JAMES D. | EVP, CIO | Buy | 1,397 | — | — |
| 2026-02-15 | SWANSON, JAMES D. | EVP, CIO | Sale | 709 | — | — |
| 2026-02-15 | SWANSON, JAMES D. | EVP, CIO | Sale | 492 | — | — |
| 2026-02-15 | SWANSON, JAMES D. | EVP, CIO | Buy | 19,449 | — | — |
| 2026-02-15 | SWANSON, JAMES D. | EVP, CIO | Buy | 709 | — | — |
| 2026-02-15 | SWANSON, JAMES D. | EVP, CIO | Buy | 492 | — | — |
| 2026-02-15 | SWANSON, JAMES D. | EVP, CIO | Sale | 309 | $243.45 | $75226.05 |
| 2026-02-15 | SWANSON, JAMES D. | EVP, CIO | Sale | 214 | $243.45 | $52098.30 |
| 2026-02-15 | SCHMID, TIMOTHY | EVP, WW Chair, MedTech | Buy | 2,548 | — | — |
Frequently asked questions
Are JNJ insiders buying or selling?
Over the transactions on record, JNJ insiders have been net sellers, with about $105.09M in stock sold across 53 sales, against 18 open-market purchases.
Does insider selling at JNJ mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which JNJ insiders are selling the most?
Recent selling is concentrated in a few names. DUATO, JOAQUIN accounts for the largest share on record, with about $44.71M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.